Decrease in high density lipoprotein cholesterol (HDL-C) levels following gemfibrozil therapy

Andras G. Lacko, Bhalchandra J. Kudchodkar, Wayne W. Loney, Michael B. Clearfield, Stephen Weis

Research output: Contribution to journalArticle

Abstract

This report represents the continuation of our studies on the effects of gemfibrozil therapy on high density lipoprotein cholesterol levels. Previously, we reported that despite an impressive mean increase in high density lipoprotein cholesterol (20%), the response to 12 weeks of gemfibrozil therapy was highly variable. Accordingly, out of the 27 subjects studied, five actually had lower high density lipoprotein cholesterol at the conclusion of therapy compared to baseline values. The changes observed in plasma lipids, combined with correlational relationships suggest that the conversion of triglyceride rich lipoprotein components into high density lipoprotein may be impaired in those subjects that respond poorly or negatively to gemfibrozil therapy.

Original languageEnglish
Pages (from-to)389-392
Number of pages4
JournalClinical Chemistry and Laboratory Medicine
Volume36
Issue number6
DOIs
StatePublished - 28 Aug 1998

Fingerprint

Gemfibrozil
HDL Cholesterol
HDL Lipoproteins
Lipoproteins
Triglycerides
Therapeutics
Lipids
Plasmas

Keywords

  • Gemfibrozil therapy
  • High density lipoprotein cholesterol
  • Triglycerides

Cite this

Lacko, Andras G. ; Kudchodkar, Bhalchandra J. ; Loney, Wayne W. ; Clearfield, Michael B. ; Weis, Stephen. / Decrease in high density lipoprotein cholesterol (HDL-C) levels following gemfibrozil therapy. In: Clinical Chemistry and Laboratory Medicine. 1998 ; Vol. 36, No. 6. pp. 389-392.
@article{947fbbd561a440d5be5b5da144b7153a,
title = "Decrease in high density lipoprotein cholesterol (HDL-C) levels following gemfibrozil therapy",
abstract = "This report represents the continuation of our studies on the effects of gemfibrozil therapy on high density lipoprotein cholesterol levels. Previously, we reported that despite an impressive mean increase in high density lipoprotein cholesterol (20{\%}), the response to 12 weeks of gemfibrozil therapy was highly variable. Accordingly, out of the 27 subjects studied, five actually had lower high density lipoprotein cholesterol at the conclusion of therapy compared to baseline values. The changes observed in plasma lipids, combined with correlational relationships suggest that the conversion of triglyceride rich lipoprotein components into high density lipoprotein may be impaired in those subjects that respond poorly or negatively to gemfibrozil therapy.",
keywords = "Gemfibrozil therapy, High density lipoprotein cholesterol, Triglycerides",
author = "Lacko, {Andras G.} and Kudchodkar, {Bhalchandra J.} and Loney, {Wayne W.} and Clearfield, {Michael B.} and Stephen Weis",
year = "1998",
month = "8",
day = "28",
doi = "10.1515/CCLM.1998.066",
language = "English",
volume = "36",
pages = "389--392",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH",
number = "6",

}

Decrease in high density lipoprotein cholesterol (HDL-C) levels following gemfibrozil therapy. / Lacko, Andras G.; Kudchodkar, Bhalchandra J.; Loney, Wayne W.; Clearfield, Michael B.; Weis, Stephen.

In: Clinical Chemistry and Laboratory Medicine, Vol. 36, No. 6, 28.08.1998, p. 389-392.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Decrease in high density lipoprotein cholesterol (HDL-C) levels following gemfibrozil therapy

AU - Lacko, Andras G.

AU - Kudchodkar, Bhalchandra J.

AU - Loney, Wayne W.

AU - Clearfield, Michael B.

AU - Weis, Stephen

PY - 1998/8/28

Y1 - 1998/8/28

N2 - This report represents the continuation of our studies on the effects of gemfibrozil therapy on high density lipoprotein cholesterol levels. Previously, we reported that despite an impressive mean increase in high density lipoprotein cholesterol (20%), the response to 12 weeks of gemfibrozil therapy was highly variable. Accordingly, out of the 27 subjects studied, five actually had lower high density lipoprotein cholesterol at the conclusion of therapy compared to baseline values. The changes observed in plasma lipids, combined with correlational relationships suggest that the conversion of triglyceride rich lipoprotein components into high density lipoprotein may be impaired in those subjects that respond poorly or negatively to gemfibrozil therapy.

AB - This report represents the continuation of our studies on the effects of gemfibrozil therapy on high density lipoprotein cholesterol levels. Previously, we reported that despite an impressive mean increase in high density lipoprotein cholesterol (20%), the response to 12 weeks of gemfibrozil therapy was highly variable. Accordingly, out of the 27 subjects studied, five actually had lower high density lipoprotein cholesterol at the conclusion of therapy compared to baseline values. The changes observed in plasma lipids, combined with correlational relationships suggest that the conversion of triglyceride rich lipoprotein components into high density lipoprotein may be impaired in those subjects that respond poorly or negatively to gemfibrozil therapy.

KW - Gemfibrozil therapy

KW - High density lipoprotein cholesterol

KW - Triglycerides

UR - http://www.scopus.com/inward/record.url?scp=0031848816&partnerID=8YFLogxK

U2 - 10.1515/CCLM.1998.066

DO - 10.1515/CCLM.1998.066

M3 - Article

C2 - 9711427

AN - SCOPUS:0031848816

VL - 36

SP - 389

EP - 392

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

IS - 6

ER -